Global Schizophrenia Drugs (Orals & Injectables) Market: Insights, Trends and Forecast (2019-2023)

DELHI, India - Oct. 18, 2019 - PRLog -- The global schizophrenia market is estimated to reach US$10.43 billion in 2023, growing at a CAGR of 3.69%, for the period spanning from 2018 to 2023. The factors such as rising occurrence of schizophrenia, surging chronic ailments incidence, increasing personal healthcare expenditure, accelerating economic growth and unmet medical needs are expected to drive the market growth. However, growth of the industry would be challenged by stringent regulations, patient health-associated risk, associated business risk and limited access to patent rights. A few notable trends include rising pharmaceutical R&D spending, intensifying e-commerce pharmaceutical products sales, progressing schizophrenia drugs pipeline and rising adoption of somatic therapy.

On the basis of mode of administration, schizophrenia market has been segmented into long acting injections and oral. Amongst them, owing to effective long-term relapse prevention, increased patient compliance, ease of administration and reduced hospitalization rates, long acting injections are widely used for managing or treating schizophrenia patients.

The fastest growing regional market is Americas owing to continuous advancement in the second & third generation anti-psychotic drugs, increasing schizophrenia population and development of economical long acting drugs by local manufacturers in US and Canada. The US is the largest market and is already well-penetrated at developed market levels.

Scope of the report:

• The report provides a comprehensive analysis of the global schizophrenia market, segmented on the basis of mode of administration i.e. oral & long acting injections, by therapeutic class i.e. second generation & third generation anti-psychotics and drug type i.e. Invega Sustenna, Latuda, Arsitada & Rexulti.

• The major regional markets (Americas, Europe and Asia-Pacific) have been analysed, along with country coverage of the U.S, Germany and Japan.

• The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.

• The competitive landscape of the market, along with the company profiles of leading players (Allergan Plc, Johnson & Johnson, Otsuka Holdings Co., Ltd., Sumitomo Chemical Co., Ltd., Alkermes Plc and Acadia Pharmaceuticals Inc.) are also presented in detail.

For more Information:

https://www.konceptanalytics.com/Researchreport/global-schizophrenia-drugs-orals-injectables-market-insights-trends-and-forecast-2019-2023-45664.aspx

Koncept Analytics

Vikas Gupta

(Business Development Manager)

FFCS-36, Ansal Plaza

Vaishali, Ghaziabad

U.P - 201010

Tele: +91-120-4130959

Mobile: +91-9871694789

Mail ID – vikas@konceptanalytics.com